

# **EAACI** Allergy School **Insect Venom Allergy and Mastocytosis**

11 - 13 April 2019

Groningen, the Netherlands

## **Scientific Programme**

### Thursday, 11 April 2019

12:00 - 14:00	Registration and Light Lunch
14:00 - 14:15	Welcome address Hanneke Oude Elberink, The Netherlands   Dario Antolin Amerigo, Spain   Christoph Schrautzer, Austria
14:15 - 15:30	Session I - What is allergy?  Chairs: Hanneke Oude Elberink, The Netherlands   Christoph Schrautzer, Austria
14:15 - 15:30	The Mast cell- IgE paradox, from homeostasis to anaphylaxis Speaker: Stephen Galli, United States
15:30 - 16:00	Coffee break
16:00 - 18:00	Session II - Natural history of hypersensitivity reactions to stings and quality of life: who is at risk and risk perception Chairs: Dario Antolin Amerigo, Spain   Stephen Joseph Galli, United States

16:00 - 16:15	The impact of sting reactions on quality of life Hanneke Oude Elberink, The Netherlands
16:15 - 16:45	Hymenoptera allergy: let's start from the beginning Arantza Vega, Spain
16:45 - 17:30	Natural history of systemic reactions in children and adults Dario Antolin Amerigo, Spain
17:30 - 18:00	Who is really in needs for an EAI and/or VIT?  Hanneke Oude Elberink, The Netherlands
18:30 - 20:30	Welcome reception

## Friday, 12 April 2019

09:30 - 11:30	Session III - Diagnostic Tools Chairs: Beatrice Biló, Italy   Franziska Ruëff, Germany
09:30 - 10:15	Allergen venom components for the selection of the venom - sensitivity matters!  Markus Ollert, Luxembourg
10:15 - 10:45	The additional value of cellular tests in insect venom allergy Peter Korošec, Slovenia
10:45 - 11:15	Dealing with cross-reactivity: how to detect the right venom for the right patient Thilo Jakob, Germany
11:15 - 11:30	A21/O01 - Fluorescent Labelling Of Major Honeybee Allergens Api M 1 And Api M 2 With Quantum Dots And Development Of Multiplex Basophil Activation Test Ana Koren, Slovenia
11:30 - 12:00	Coffee break
12:00 - 13:30	Session IV - Risk factors and Mastocytosis Chairs: Hanneke Oude Elberink, The Netherlands   David González De Olano, Spain
12:00 - 12:30	Alpha-tryptasemia: is there a link with instect venom allergy, mastocytosis and mast cell activation syndrome? Vito Sabato, Belgium
12:30 - 13:15	Mastocytosis as a risk factor for insect venom allergy Patrizia Bonadonna, Italy
13:15 - 13:30	A32/O02 - Pulling The Trigger In Clonal Mast Cell Disorders: Are Hymenoptera Stings The Only Actors?  Gustavo Jorge Molina Molina, Spain

#### 13:30 - 14:30 Lunch & Poster discussion Session

#### Poster Walk 1:P01 - P07

Chair: Franziska Ruëff, Germany

A09/P01 - Predictors Of Severe Anaphylactic Reactions In Patients With Hymenoptera Venom Allergy

Maria Chapsa, Germany

A10/P02 - Systemic Mastocytosis In A 5 Year Old Child Presenting With Hypovolemic Shock, Succeeded By Severe Anaphylaxis To Fentanyl *Inger F Bocca-Tjeertes, The Netherlands* 

A14/P03 - Insect-Venom Elicited Anaphylaxis, A Prospective Cohort Study From The European Anaphylaxis Registry

Wojciech Francuzik, Germany

A15/P04 - Do We Need Premedication With Omalizumab In Patients With Systemic Mastocytosis Having Venom Immunotherapy?

Asli Gelincik, Turkey

A20/P05 - Omalizumab In Immunotherapy With Hymenoptera Venom Cristiana Ferreira, Portugal

A34/P06 - Evaluation Of Systemic Mastocytosis With 3 Cases

Betül Ayse Sin, Turkey

A40/P07 - Risk Factors In Hymenoptera Venom Allergy

Svetlana Shvets, Russia

#### Poster Walk 2: P08 - P14

Chair: Markus Ollert, Luxembourg

A18/P08 - Contribution Of Component Resolved Diagnosis In Hymenoptera Venom Allergy

Asli Gelincik, Turkey

A22/P09 – Sensitization To Bee Venom In Non-allergic Beekeepers Ana Margarida Mesquita, Portugal

A24/P10 - Molecular Diagnosis And Beyond Unmet Needs In Rush Immunotherapy For Hymenoptera Venom – Single Center Experience In Albania

Mehmet Hoxha, Albania

A27/P11 - Contribution Of Molecular Diagnosis Of Bee Venom Allergic Patients With Systemic Reactions During Venom Immunotherapy

Tatiana Lourenço, Portugal

A28/P12 - Omalizumab In Immunotherapy With Hymenoptera Venom-Case Report

Mara Fernandes, Portugal

A30/P14 - Soluble FcɛRI Is A Potential Biomarker Of IgE Mast Cell Desensitization During Chemotherapy Treatment Of Allergic Cancer Patients Sherezade Moñino-Romero, Austria

Poster	Walk	3. D1	5 _	D21
Puster	vvaik	3: PJ	L <b>3</b> —	PZI

Chair: Vito Sabato, Belgium

A19/P15 - The Need Of Bee Venom Immunotherapy Reintroduction Due To

Unsuccessful 5-Year-Lasting Treatment In Adolescent Boy

Ewa Cichocka-Jarosz, Poland

A25/P16 - Multicenter Study Of Clinical Relevance Of Recombinant Allergen Api M 1 And Ves V 5 Determined By IgE Multiplex Test ImmunoCAP ISAC

Urska Bidovec-Stojkovic, Slovenia

A31/P17 - Systemic Mastocytosis With Low Serum Tryptase: A Challenging

Diagnosis

Tiago Azenha Rama, Portugal

A33/P18 - Kounis Syndrome: A Thought-Provoking Case Report

Francesca Rizzo, Italy

A37/P20 - Three Is A Charm!

Toon Ieven, Belgium

A39/P21 - Hymenoptera Species: Who's Eating And Stinging?

Arantza Vega, Spain

#### 14:30 - 16:15 Session V - Venom immunotherapy

Chair: Christoph Schrautzer, Austria | Markus Ollert, Luxembourg

14:30 - 15:00 Venom immunotherapy across the world

Beatrice Biló, Italy

15:00 - 15:30 When can we stop venom immunotherapy?

Franziska Ruëff, Germany

15:30 - 16:00 How about VIT in Mastocytosis patients?

David González De Olano, Spain

16:00 – 16:15 A38/003 - Mastocytosis And Anaphylaxis To Hymenoptera Venom: A Single

Center Cohort Study

Christine Breynaert, Belgium

#### 16:15 - 16:30 Coffee break

#### 16:30 - 18:20 Session VI - Practical workshops

Preliminary Room Topic 1: Mastocytosis as separate disease entity

Moderator: Patrizia Bonadonna, Italy | Hanneke Oude-Elberink, The

Netherlands

Room 17 Topic 2: Different treatment schedules and dealing with side effects

Moderator: Dario Antolin Amerigo, Spain

Room 18 Topic 3: Difficult cases

Moderator: Carmen Moreno-Aguilar, Spain

16:30-17:00	Workshop round 1
17:00-17:10	Rotation break
17:10-17:40	Workshop round 2
17:40-17:50	Rotation break
17:50-18:20	Workshop round 3
19:00 - 22:00	Dinner

## Saturday, 13 April 2019

Saturday, 13 April 2019		
08:30 - 10:30	Session VII - Behind the scenes of insect hypersensitivity Chairs: Kymble Martin Spriggs, Australia   Arantza Vega Castro, Spain	
08:30 - 09:15	Insect stings and bites: not only Hymenoptera  Hanneke Oude Elberink, The Netherlands	
09:15 - 10:00	Mechanisms of allergy: how does early and long VIT protection work Markus Ollert, Luxembourg	
10:00 - 10:15	A36/O04 - Sting-Challenge Demonstrated Tolerance In Patients Undergoing Ant Venom Specific Immunotherapy, Validating New Centre Approach Kymble Martin Spriggs, Australia	
10:15 - 10:30	A26/O05 - Absence Of Th2 Cell Suppression After Induction Of Venom Immunotherapy In Wasp-Venom Allergic, Indolent Systemic Mastocytosis Patient	
	Merel C. Onnes, The Netherlands	
10:30 - 11:00	Coffee break	
11:00 - 12:30	Session VIII - Open issues Chairs: Christoph Schrautzer, Austria   Markus Ollert, Luxembourg	
11:00 - 11:30	Efficacy and safety of an accelerated outpatient protocol for venom immunotherapy  Christoph Schrautzer, Austria	
11:30 - 12:00	How to deal in an optimal way with the complexity of bee venom allergy?  Markus Ollert, Luxembourg	
12:00 - 12:15	A23/O06 - Predictors Of Severe Cardiovascular Honey-Bee Sting Reaction With Absence Of Skin Symptoms In Patients With Normal Baseline Serum Tryptase Levels  Peter Kopac, Slovenia	
12:15 - 12:30	Open questions and future strategies in insect venom allergy Chairs: Christoph Schrautzer, Austria   Markus Ollert, Luxembourg	
12:30 - 12:45	Closing remarks  Hanneke Oude Elberink, The Netherlands   Dario Antolin Amerigo, Spain	